| Literature DB >> 29186905 |
Kamal Rahimizadeh1, Hadi AlShamaileh2, Milena Fratini3, Madhuri Chakravarthy4,5, Michelle Stephen6, Sarah Shigdar7, Rakesh N Veedu8,9.
Abstract
Systematic evolution of ligands by exponential enrichment (SELEX) is an established procedure for developing short single-stranded nucleic acid ligands called aptamers against a target of choice. This approach has also been used for developing aptamers specific to whole cells named Cell-SELEX. Aptamers selected by Cell-SELEX have the potential to act as cell specific therapeutics, cell specific markers or cell specific drug delivery and imaging agents. However, aptamer development is a laborious and time-consuming process which is often challenging due to the requirement of frequent optimization of various steps involved in Cell-SELEX procedures. This review provides an insight into various procedures for selection, aptamer enrichment, regeneration and aptamer-binding analysis, in addition to a very recent update on all aptamers selected by Cell-SELEX procedures.Entities:
Keywords: Cell-SELEX; aptamer enrichment; aptamers; binding assays; ssDNA
Mesh:
Substances:
Year: 2017 PMID: 29186905 PMCID: PMC6149766 DOI: 10.3390/molecules22122070
Source DB: PubMed Journal: Molecules ISSN: 1420-3049 Impact factor: 4.411
Figure 1Schematic illustration showing the steps involved in Cell-SELEX. A. Incubation of cells with an aptamer library; B. Isolating bound sequences from unbound sequences; C. Elution of bound sequences; D. Negative selection to remove non-specific sequences; E. Amplification of target specific sequences; F. Sequencing of the selected aptamer pool.
Figure 2DNA strand separation using magnetic beads. A. Immobilization of the double stranded sequences on the magnetic beads; B. Denaturation of the double stranded DNA by NaOH treatment; C. Purification of the unbound sequences.
Figure 3Generation of ssDNA with lambda exonuclease. A. Adding enzyme to dsDNA which has a phosphate group; B. Incubate enzyme with dsDNA; C. Extract and purify the ssDNA.
Summary of different Cell-SELEX experiments performed in the last few years.
| Aptamer | Method | Target Cell | Kd (nM) | Reference |
|---|---|---|---|---|
| RNA | Cell-SELEX | HER-2-overexpressing breast cancer | 94.6 | [ |
| DNA | Cell-SELEX | Acute myeloid leukemia cells | 5.4 ± 1.6 | [ |
| RNA | Cell-SELEX | Mouse embryonic stem cells | - | [ |
| DNA | Cell-SELEX | Human hepatocarcinoma | 19–450 | [ |
| RNA | Cell-SELEX | AC133-epitope of CD133 expressed on HEK293T cells | 33.85–145 | [ |
| DNA | Cell-SELEX | Over-expressing epidermal growth factor receptor variant III on human glioblastoma | ≤100 | [ |
| DNA | on-chip Cell-SELEX | Different histologically classified ovarian cancer cells | 1.3 | [ |
| DNA | Cell-SELEX | Epidermal growth factor receptor variant III on Glioblastoma | 3.37 ± 0.98 | [ |
| DNA | Cell-SELEX | Metastatic colorectal cell | 8.1 ± 0.9 | [ |
| DNA | Cell-SELEX | Prostate cancer cells | 73.59 ± 11.01 | [ |
| RNA | Cell-SELEX | Annexin A2 | 10.5 ± 4.6 | [ |
| DNA | Cell-SELEX By flow cytometry | 3T3-L1 adipocytes cells | 33.1 ± 2.9 | [ |
| RNA | Cell-SELEX | PC3-prostate cancer cell | 71.57 ± 12.96 | [ |
| DNA | Cell-SELEX | Human hepatoma cells HepG2 | 64–349 | [ |
| DNA | On-chip Cell-SELEX | Colorectal cancer cells | 12.3 | [ |
| DNA | Cell-SELEX | Hepatocellular carcinoma | 9.4 ± 2.0 | [ |
| DNA | Cell internalization SELEX | MCF10CA1h human breast ductal carcinoma | [ | |
| DNA | Cell-SELEX | Nasopharyngeal carcinoma cell lines | 11.93 ± 1.40 | [ |
| DNA | Cell-SELEX | Renal cell carcinoma (768-O) | 9.4 ± 2.0 | [ |
| DNA | Cell-SELEX | Metastatic colorectal carcinoma LOVO cells | 167.3 ± 30.2 | [ |